




Mouse Anti-Feline CD4

Cat. No.	Format	Size
8130-01	Purified (UNLB)	0.5 mg
8130-02	Fluorescein (FITC)	0.5 mg
8130-08	Biotin (BIOT)	0.5 mg
8130-09	R-phycoerythrin (PE)	0.1 mg



Feline peripheral blood lymphocytes were stained with Mouse Anti-Feline CD4-PE (SB Cat. No. 8130-09) and Mouse Anti-Feline CD8-FITC (SB Cat. No. 8120-02).

Overview

Clone	3-4F4 (Fel7)
Isotype	Mouse IgG ₁ κ
Immunogen	Feline T cells
Specificity	Feline/Lion CD4; Mr 65 kDa
Alternate Name(s)	fCD4

Description

Feline CD4, a member of the immunoglobulin superfamily of cell surface receptors, is a type I transmembrane glycoprotein that is expressed on the helper/inducer subpopulation of peripheral T lymphocytes. It is present on approximately 55% of thymocytes, 15% of splenocytes, 40% of lymph node cells, and 25% of peripheral blood lymphocytes. CD4 functions as an accessory molecule in the recognition of foreign antigens in association with MHC Class II antigens by T cells.

Applications

FC – Quality tested ^{1,4,7-31}
 IHC-FS – Reported in literature ³⁻⁵
 ICC – Reported in literature ²
 IP – Reported in literature ^{1,2}
 Sep – Reported in literature ⁶
 Block – Reported in literature ¹

Working Dilutions

Flow Cytometry	FITC and BIOT conjugates	≤ 1 µg/10 ⁶ cells
	PE conjugate	≤ 0.2 µg/10 ⁶ cells
For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL		

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Ackley CD, Hoover EA, Cooper MD. Identification of a CD4 homologue in the cat. *Tissue Antigens*. 1990;35:92-8. (Immunogen, FC, IP, Block)
2. Shimojima M, Morikawa S, Maeda K, Tohya Y, Miyazawa T, Mikami T. Generation of monoclonal antibodies against a feline CD antigen (CD4) expressed by a recombinant baculovirus. *J Vet Med Sci*. 1997;59:467-9. (IP, ICC)
3. Rideout BA, Lowenstine LJ, Hutson CA, Moore PF, Pedersen NC. Characterization of morphologic changes and lymphocyte subset distribution in lymph nodes from cats with naturally acquired feline immunodeficiency virus infection. *Vet Pathol*. 1992;29:391-9. (IHC-FS)
4. Femenia F, Crespeau F, Fontaine JJ, Boucheix C, Parodi AL. Early haematological and pathological abnormalities of pathogen-free cats experimentally infected with feline immunodeficiency virus (FIV). *Vet Res*. 1994;25:544-54. (IHC-FS, FC)
5. Fox JG, Perkins S, Yan L, Shen Z, Attardo L, Pappo J. Local immune response in *Helicobacter pylori*-infected cats and identification of *H. pylori* in saliva, gastric fluid and faeces. *Immunology*. 1996;88:400-6. (IHC-FS)
6. Choi I, Hokanson R, Collisson EW. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8⁺ T lymphocytes suppresses FIV replication. *J Virol*. 2000;74:676-83. (Sep)
7. Spencer JA, Bouic PD, Espie I, Colly L. A comparison between T-helper (CD4) and T-suppressor (CD8) cell ratios in FIV positive and negative lions *Panthera leo* and domestic cats *Felis catus*. *S Afr J Wildl Res*. 1995;25:111-2. (FC, Lion Reactivity)
8. Hohdatsu T, Hirabayashi H, Motokawa K, Koyama H. Comparative study of the cell tropism of feline immunodeficiency virus isolates of subtypes A, B and D classified on the basis of the env gene V3-V5 sequence. *J Gen Virol*. 1996;77:93-100. (FC)
9. Shimojima M, Miyazawa T, Kohmoto M, Ikeda Y, Nishimura Y, Maeda K, et al. Expansion of CD8 α + β - cells in cats infected with feline immunodeficiency virus. *J Gen Virol*. 1998;79:91-4. (FC)
10. Phipps AJ, Hayes KA, Buck WR, Podell M, Mathes LE. Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. *J Acquir Immune Defic Syndr*. 2000;23:8-16. (FC)
11. Hokanson RM, TerWee J, Choi I, Coates J, Dean H, Reddy DN, et al. Dose response studies of acute feline immunodeficiency virus PPR strain infection in cats. *Vet Microbiol*. 2000;76:311-27. (FC)
12. Barr MC, Billaud J, Selway DR, Huitron-Resendiz S, Osborn KG, Henriksen SJ, et al. Effects of multiple acute morphine exposures on feline immunodeficiency virus disease progression. *J Infect Dis*. 2000;182:725-32. (FC)
13. Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. *J Infect Dis*. 2000;181:576-86. (FC)
14. Hohdatsu T, Yamazaki A, Yamada M, Kusuhara H, Kaneshima T, Koyama H. Ability of CD8⁺ T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4⁺ T cell counts and plasma viremia. *Microbiol Immunol*. 2003;47:765-73. (FC)
15. Howard KE, Fisher IL, Dean GA, Burkhard MJ. Methodology for isolation and phenotypic characterization of feline small intestinal leukocytes. *J Immunol Methods*. 2005;302:36-53. (FC)
16. Broche-Pierre S, Richardson J, Morailon A, Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. *J Gen Virol*. 2005;86:2495-506. (FC)
17. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. *J Virol*. 2005;79:1036-44. (FC)
18. Brennan G, Podell MD, Wack R, Kraft S, Troyer JL, Bielefeldt-Ohmann H, et al. Neurologic disease in captive lions (*Panthera leo*) with low-titer lion lentivirus infection. *J Clin Microbiol*. 2006;44:4345-52. (FC, Lion Reactivity)
19. Dean GA, LaVoy A, Yearley J, Stanton C. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats. *J Infect Dis*. 2006;193:1520-7. (FC)
20. El Garch H, Richard S, Piras F, Leard T, Poulet H, Andreoni C, et al. Feline leukemia virus (FeLV)-specific IFN γ T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. *Int J Appl Res Vet Med*. 2006;4:100-8. (FC)
21. Howard KE, Burkhard MJ. FIV infection induces unique changes in phenotype and cellularity in the medial iliac lymph node and intestinal IEL. *AIDS Res Hum Retroviruses*. 2007;23:720-8. (FC)
22. Howard KE, Burkhard MJ. Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems. *Immunology*. 2007;122:571-83. (FC)
23. Münk C, Zielonka J, Constabel H, Kloke B, Rengstl B, Battenberg M, et al. Multiple restrictions of human immunodeficiency virus type 1 in feline cells. *J Virol*. 2007;81:7048-60. (FC)
24. Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, et al. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. *Virus Res*. 2007;127:9-16. (FC)
25. Carreño AD, Mergia A, Novak J, Gengozian N, Johnson CM. Feline immunodeficiency virus associated with depletion of naïve (CD45RA⁺) CD4⁺ lymphocytes from the blood of domestic cats during acute pediatric infection. *Vet Immunol Immunopathol*. 2008;121:161-8. (FC)
26. Maksiereekul S, Dubie RA, Shen X, Kieu H, Dean GA, Sparger EE. Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF- α plasmids preserves global CD4 T lymphocyte function after challenge with FIV. *Vaccine*. 2009;27:3754-65. (FC)
27. Mikkelsen SR, Reckling SK, Egan EA, Dean GA. In vivo depletion of CD4⁺CD25^{hi} regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus. *Virology*. 2010;403:163-72. (FC)
28. Thompson J, MacMillan M, Boegler K, Wood C, Elder JH, Vandewoude S. Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. *PLoS One*. 2011;6(8):e24020. (FC)
29. Simões RD, Howard KE, Dean GA. In vivo assessment of natural killer cell responses during chronic feline immunodeficiency virus infection. *PLoS One*. 2012;7(5):e37606. (FC)
30. Quimby JM, Webb TL, Habenicht LM, Dow SW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. *Stem Cell Res Ther*. 2013;4:48. (FC)
31. Trzil JE, Masseur I, Webb TL, Chang C, Dodam JR, Cohn LA, et al. Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma. *Clin Exp Allergy*. 2014;44:1546-57. (FC)